{
  "item1": "intend continue broaden scope products services provide across drug discovery non-clinical development continuum primarily through internal development, also, through focused acquisitions strategic partnerships strategy, all which intended enable us flexibility adapt innovate meet client’s changing needs. Acquisitions, such acquisitions Explora BioLabs fiscal 2022, SAMDI 2023, Noveprim 2023, been (and expect will future) integral part growth strategy, both expand portfolio broaden geographic footprint. committed disciplined approach seeks target businesses sound strategic fit. aim consistently deliver shareholder value, including achievement hurdle rate return invested capital above weighted average cost capital.",
  "item7": "Critical Accounting Policies Estimates accounting policy deemed critical if nature estimates assumptions material due levels subjectivity judgment necessary account highly uncertain matters susceptibility such matters change, impact estimates assumptions consolidated financial statements may material. believe following represent critical accounting policies estimates used preparation financial statements: Revenue recognized when, as, obligations under terms contract satisfied, which occurs when control promised products services transferred customers. Revenue measured amount consideration expect receive exchange transferring products services customer (“transaction price”). extent transaction price includes variable consideration, estimate amount variable consideration should included transaction price utilizing amount which expect entitled.",
  "item2": "Item 2. Management’s Discussion Analysis Financial Condition Results Operations leading, full service, non-clinical global drug development partner. over 75 years, been business providing research models required research development new drugs, devices, therapies. Over time, built upon original core competency laboratory animal medicine science (research model technologies) develop diverse portfolio discovery safety assessment services, both Good Laboratory Practice (GLP) non-GLP, supports clients target identification through non-clinical development."
}